Page 121 - TNFlipTest

Toronto Notes 2019
References
Cardiology and Cardiac Surgery C53
Trial
ARRHYTHMIA
AFFIRM
AF-CHF ARISTOTLE ENGAGE AF-TIMI48 RE-LY
ROCKET-AF
HYPERTENSION
HYVET
SIPLICITY-HTN 3 SPRINT
UKHDS (UKPDS) VALUE
Reference
Results
NEJM 2002;347:1825-33 NEJM 2008;358:2667-77 NEJM 2011;365:981-92 NEJM 2013;369:2093-2104 NEJM 2009;361:1139-51 NEJM 2011;365:883-891
NEJM 2008;358:1887-98 NEJM 2014;370:1393-1401
NEJM 2015;373:2103-2116 BMJ 1998;317:703-13 Lancet 2004;363:2022-2031
No significant difference in mortality rates between rate or rhythm control of AFib
In patients with AFib and CHF, there is no significant difference in mortality rates from cardiovascular causes between rate and rhythm control
AFib patients treated with apixaban had a lower incidence of stroke, major bleeding and mortality compared to warfarin
AFib patients treated with edoxaban had similar rates of stroke and lower rates of major bleeding compared to warfarin
AFib patients treated with dabigatran had a lower incidence of stroke compared to warfarin, with similar rates of major bleeding
In patients with AFib rivoxabarin is non-inferior to warfarin for stroke prevention, and major and non-major bleeding
In hypertensive patients >80 yr treatment with indapamide, with or without perindopril, showed a trend towards reduced relative risk of fatal or non-fatal stroke
Renal denervation does not reduce blood pressure in patients with resistant hypertension compared to sham procedure
In patients with high risk of cardiovascular events excluding diabetes, strict systolic BP control (<120 mmHg) is associated with fewer cardiovascular events and lower all-cause mortality
Hypertensive patients with DM and tight BP control at <150/85 mmHg by use of ACEI or β-blocker reduced risk of diabetic complications and death related to DM and reduced risk of end-organ damage
Valsartan group had higher incidence of MI than amlodipine group, whereas amlodipine had a higher incidence of new-onset DM
References
Ischemic Heart Disease
CannonCP,BraunwaldE,McCabeCH,etal.Intensiveversusmoderatelipidloweringwithstatinsafteracutecoronarysyndromes.NEJM2004;350:1495-504.
Lindahl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. NEJM 2000;343:1139-1147.
Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. NEJM 2003;348:1309- 1321.
Rauch U, Osende JI, Fuster V, et al. Thrombus formation on the atherosclerotic plaques: pathogenesis and clinical consequences. Ann Intern Med 2001;134:224-238. Spinler S, Rees C. Review of prasugrel for the secondary prevention of atherothrombosis. J Manag Care Pharm 2009;15:383-95.
The Arterial Revascularization Therapies Study Group. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. NEJM 2001;344:1117-1124.
Turpie AGG, Antman EM. Low-molecular-weight heparins in the treatment of acute coronary syndromes. Arch Intern Med 2001;161:1484-1490. Yeghiazarians Y, Braunstein JB, Askari A, et al. Review article: unstable angina pectoris. NEJM 2000;342:101-114.
Cardiomyopathies
Feldman AM, McNamara D. Myocarditis (review). NEJM 2000;343:1388-1398.
Guidelines
2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Can J Cardiol 2017;33:1342-1433.
2017 ESC/EACTS guidelines for the management of valvular heart disease. EHJ 2017; 36:2739-2791.
2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. EHJ 2016;37:2893-2962.
2014 ACC/AHA guideline for the management of patients with non–ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. JACC 2014;64:e139-228.
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. JACC 2013;61:e78-140.
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease. JACC 2012;60:e44-e164. ACC/AHA guidelines for percutaneous coronary intervention. Circulation 2001;103:3019-3041.
ACCF/AHA 2009 focused update on the guidelines for the diagnosis and management of heart failure in adults. Circulation 2009;119:1977-2016.
ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004;110:e82-292. American College of Cardiology (clinical guidelines, etc). Available from: http://www.acc.org.
Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial Infarction – summary: a report of the American College of Canadian Cardiovascular Society (CCS) mobile guidelines. Available from: http://www.ccs.ca/mobile.Free.
Aurigemma GP, Gaasch WH. Clinical practice, diastolic heart failure. NEJM 2004;351:1097.
Beard JD. Chronic lower limb ischemia. BMJ 2000;320:854-857.
Canadian Cardiovascular Society 2005 Consensus Conference Peripheral Arterial Disease (Draft). Available from: http://www.ccs.ca.
Cardiology. American Heart Association Task Force on practice guidelines. Circulation 2004;110-588.
Cardiology Online. Available from: http://www.theheart.org.
CCS focused 2012 update of the CCS atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012;28:125-136.
CCS. The use of antiplatelet therapy in the outpatient setting: CCS guidelines. Can J Cardiol 2011;27:S1-S59.
CCS. 2001 Canadian cardiovascular society consensus guideline update for the management and prevention of heart failure. Can J Cardiol 2001;17(suppE):5-24.
CCS 2000 Consensus Conference: Women and ischemic heart disease. Can J Cardiol 2000:17(suppl D).
Harrington RA, Becker RC, Ezekowitz M, et al. Antithrombotic therapy for coronary artery disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126(3 suppl):513s-584s.
Heart valve repair. Available from: http:// www.heartvalverepair.net.
May J, White GH, Harris JP. The complications and downside of endovascular therapies. Adv Surg 2001;35:153-172.
Rutherford RB. Vascular surgery, 4th ed. Toronto: WB Saunders, 1995. Chapter: Atherogenesis and the medical management of atherosclerosis. p222-234.
Schmieder FA, Comerota AJ. Intermittent claudication: magnitude of the problem, patient evaluation, and therapeutic strategies. Am J Card 2001;87(Suppl):3D-13D.
Simpson C, Dorian P, Gupta A, et al. Assessment of the cardiac patient for fitness to drive and fly: executive summary. Can J Cardiol 2004;20:1313-1323.
Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2851-2906.